CASI - CASI Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1300
-0.0200 (-0.63%)
As of 1:19PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1400
Bid3.1300 x 1300
Ask3.1400 x 800
Day's Range3.1100 - 3.1700
52 Week Range2.8300 - 4.5800
Volume23,158
Avg. Volume123,064
Market Cap302M
Beta (3Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability
    Simply Wall St.

    CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability

    CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops...

  • Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
    Zacks

    Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

    Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

  • GuruFocus.com

    Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $64,000 of Shares

    CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share. Continue reading...

  • What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
    Simply Wall St.

    What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?

    A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful...

  • Zacks Small Cap Research

    CASI: CASI launches Evomela - first commercial product

    On August 12,2019, CASI Pharmaceuticals (CASI) announced the commercial launch of Evomela, the only approved and commercially available form of melphalan available in China. This is the Company’s first commercialized product and we are encouraged to see that volatile trade tensions between the US and China do not appear to be hampering CASI’s progress towards establishing its footprint as a leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. Sharp price decreases often go hand-in-hand with inclusion on various “approved” drug lists in China, and we believe that CASI will opt for the lower-price/higher market share route in part to suppress potential competition.

  • GuruFocus.com

    Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $507,200 of Shares

    CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share. Continue reading...

  • Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
    Zacks

    Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

    Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

  • Zacks Small Cap Research

    CASI: Making headway towards commercialization

    CASI Pharmaceuticals, Inc. (CASI) is establishing its footprint as a leading provider of high-quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. CASI’s management sees China as a sustainable opportunity and is investing with this in mind. With a robust, diverse pipeline, commitment to investing in new opportunities and ample cash, we believe that CASI Pharmaceuticals will firmly establish itself over the next several years as a leading player in China.

  • Zacks Small Cap Research

    CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond

    We initiated coverage of CASI Pharmaceuticals, Inc. (CASI) with a target price of $8.17. CASI is establishing its footprint as a leading provider of high-quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. CASI’s management sees China as a sustainable opportunity and is investing with this in mind.

  • Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
    Zacks

    Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down

    Ligand (LGND) first-quarter earnings and sales decrease year over year.

  • When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?
    Simply Wall St.

    When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?

    CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. The company’s loss has recently broadened since it announcedRead More...

  • Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
    Simply Wall St.

    Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?

    A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...